EYPT
Eyepoint Pharmaceuticals Inc
3.30$
+0.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | – | 1,972.6% | 617.0% | 693.2% | 109.9% | 14.4% | 67.6% | 199.6% | 326.9% | 275.6% | 45.5% | 54.1% | 918.5% | 214.6% | 315.9% | 13.2% | 16.9% | 22.1% | 20.1% | 10.1% | 8.6% | 6.6% | |
| 100.0% | 100.0% | 100.8% | 100.0% | 141.5% | -517.0% | 100.0% | 100.0% | 85.6% | 32.4% | 100.0% | -226.9% | -175.6% | 54.5% | 100.0% | 100.0% | 100.0% | -237.9% | 86.8% | 83.1% | 77.9% | 79.9% | 89.9% | 91.4% | 93.4% | |
| 347.7% | 1,161.6% | 780.5% | 999.8% | 607.5% | 655.6% | 576.2% | 118.6% | 34.7% | 140.9% | 199.6% | 328.5% | 275.6% | 36.0% | 45.5% | 887.7% | 197.4% | 355.6% | 75.5% | 50.6% | 77.2% | 119.9% | 140.5% | 307.2% | 704.6% | |
| – | 1,373.5% | 1,037.5% | 1,608.7% | – | – | 401.4% | 114.7% | 38.1% | 140.3% | 194.8% | 334.5% | 215.0% | 28.1% | 30.3% | 556.4% | 149.0% | 263.0% | 88.1% | 60.2% | 69.2% | 84.1% | 87.1% | 121.0% | 164.5% | |
| 100.0% | 2,451.4% | 2,430.6% | 1,728.8% | 2,812.8% | 1,190.8% | 816.4% | 138.1% | 46.1% | 233.9% | 610.6% | 334.5% | 212.8% | 30.3% | 75.8% | 1,444.1% | 346.4% | 893.5% | 321.8% | 191.4% | 227.5% | 320.5% | 253.1% | 428.5% | 869.4% | |
| -247.7% | -2,351.4% | -2,330.6% | -1,628.8% | -5,061.4% | -1,707.8% | -716.4% | -38.1% | 39.4% | -201.5% | -294.4% | -561.4% | -388.4% | 24.2% | 24.2% | -1,344.1% | -246.4% | -838.8% | -235.0% | -108.3% | -149.6% | -240.6% | -163.1% | -337.1% | -776.0% | |
| 0.0% | 1.5% | 0.6% | 0.0% | 325.7% | 531.7% | 14.6% | 4.2% | 0.0% | 0.3% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 9.6% | 12.3% | 30.3% | 21.1% | 14.9% | 7.7% | 2.7% | 0.0% | 0.1% | |
| -436.1% | -1,970.0% | -2,531.9% | -1,824.6% | -5,041.6% | -5,420.2% | -2,190.8% | -28.5% | 38.1% | -178.2% | -709.1% | -560.8% | -388.3% | 24.3% | 24.3% | -1,339.6% | -245.2% | -1,527.3% | -278.9% | -131.8% | -158.1% | -247.0% | -153.7% | -302.2% | -738.5% | |
| -347.7% | -656.3% | -440.5% | -48.2% | -667.9% | -740.9% | -13.9% | -7.8% | 0.1% | -4.4% | 4.8% | -5.5% | 3.7% | 0.4% | 0.4% | -9.6% | -10.8% | -436.4% | 30.3% | 21.1% | 14.9% | 53.8% | 0.2% | 0.2% | 0.9% | |
| -436.1% | -965.0% | -2,042.9% | -1,776.5% | -4,532.5% | -4,753.1% | -2,176.9% | -20.6% | 38.0% | -173.8% | -704.3% | -555.3% | -384.5% | 23.9% | 23.9% | -1,330.1% | -245.2% | -908.0% | -278.9% | -131.8% | -158.1% | -247.0% | -153.8% | -302.4% | -739.4% | |
| -247.7% | -2,260.5% | -1,511.7% | -1,235.7% | -4,192.2% | -1,090.8% | -716.4% | -9.9% | 53.9% | -133.9% | -231.3% | -515.0% | -364.3% | 27.5% | 27.5% | -1,288.0% | -235.6% | -793.5% | -235.8% | -103.1% | -135.8% | -233.4% | -149.9% | -298.6% | -731.1% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.